Citations

Clear

8 citation(s) found for "Chang, Kevin J".

Cost‐Effectiveness of CT Colonography Under Real‐World Colorectal Cancer Screening Adherence for Black and White Populations
Kao, Szu‐Yu Zoe , Chang, Kevin J. , Moreno, Courtney C. , Brewington, Cecelia , Bruining, David H. , Christensen, Eric , Rula, Elizabeth Y. , Sanelli, Pina C. , Chang, Kevin J , Moreno, Courtney A , Brewington, Cecelia , Christensen, Eric W , Rula, Elizabeth Y , Sanelli, Pina C , Sanmartin, Maria X. , Yee, Judy

Mayo Clinic

Cancer Medicine | November 13, 2025 | Volume: 14 | Issue: 21 | Pages: No page available

10.1002/cam4.71290 | PMID 41229177 Get It

ABSTRACT Background Given the Centers for Medicare and Medicaid Services' coverage of screening CT colonography (CTC) beginning in January 2025, we evaluated the cost‐effectiveness of CTC for colorectal cancer (CRC) screening by race (Black and White) and gender, considering real‐world screening adherence. Methods A microsimulation model compared CRC screening strategies in average‐risk adults by race and gender, incorporating 2010–2019 U.S. data on disease progression and real‐world screening adherence for colonoscopy and fecal immunochemical test (FIT). Five strategies were compared: (1) status quo (choice between colonoscopy and FIT); (2) CTC every 5 years; (3) colonoscopy every 10 years; (4) annual FIT; and (5) multitarget stool DNA test every 3 years, plus no screening. Lifetime costs, quality‐adjusted life years gained (QALYG), and incremental cost‐effectiveness ratios were projected. A willingness‐to‐pay threshold of $100,000/QALYG was used. Results Under the status quo, Black adults showed higher CRC cases and greater utilization for FIT over colonoscopy than White adults. Compared to the status quo, the CTC strategy yielded more QALYG and fewer CRC cases among Black adults, but fewer QALYG and more CRC cases among White adults. Both status quo and CTC strategies outperformed other strategies across races. The CTC strategy was the dominant strategy for Black adults. For White adults, the status quo was cost‐effective with incremental cost‐effectiveness ratios of $34,998–$73,428/QALYG, while the CTC strategy was cost saving compared to no screening. Conclusions CTC could be cost‐effective for CRC screening in Black adults under real‐world screening adherence, supporting Medicare coverage to address specific population needs and structural barriers to screening.
SAR Disease-focused Panel: Restaging Rectal Cancer MRI Synoptic Report—User Guide with Imaging Review
Sheedy, Shannon P. , Arya, Supreeta , Chang, Kevin J. , Gollub, Marc J. , Homsi, Maria El , Kim, David H. , Lalani, Tasneem, Lee, Sonia , Weiser, Martin R. , Horvat, Natally , Chang, Kevin J , Gollub, Marc , El Homsi, Maria , Khatri, Gaurav , Kim, David H , Lalani, Tasneem , Nougaret, Stephanie , Rauch, Gaiane M , Wasnik, Ashish P , Weiser, Martin , Horvat, Natally , Baheti, Akshay , Kassam, Zahra , Khatri, Gaurav , Nougaret, Stéphanie , Paroder, Viktoriya , Rauch, Gaiane M.

Mayo Clinic

RadioGraphics | October 30, 2025 | Volume: 45 | Issue: 11 | Pages: No page available

10.1148/rg.250006 | PMID 41166105 Get It

The SAR Colorectal and Anal Cancer Disease-focused Panel rectal cancer MRI restaging report template can be used to clarify common areas of confusion and deliver essential insights to ensure that clinically relevant information is effectively communicated to the treatment team.
Clinical Dementia Rating Score 0.5 Predicts Clinical Decline in Familial Frontotemporal Dementia (S48.007)
Staffaroni, Adam M. , Bonham, Luke W. , Olney, Nicholas , Attygalle, Suneth, Chang, Kevin , Kornak, John , Boxer, Adam L. , Lee, Suzee, Rosen, Howie, Spina, Salvatore , Cobigo, Yann , Binney, Richard J. , Yokoyama, Jennifer S. , Miller, Bruce L. , Boeve, Bradley F.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s48.007 Get It

Sociodemographic Factors and Screening CT Colonography Use Among Medicare Beneficiaries
Chang, Kevin J. , Moreno, Courtney C. , Bruining, David H. , Chang, Kevin J , Christensen, Eric , Sanelli, Pina C. , Rula, Elizabeth Y. , Yee, Judy

Mayo Clinic

American Journal of Roentgenology | July 19, 2023 | Volume: 222 | Issue: 1 | Pages: No page available

10.2214/ajr.23.29703 | PMID 37466190 Get It

Gender bias in postgraduate year one pharmacy letters of recommendation
Drury, Anna Sahlstrom , Bookstaver, P. Brandon , Hobbs, Brandon , Leung, Jonathan G. , Moon, Jean , Nei, Scott D. , Leung, Jonathan G , Bookstaver, P Brandon , Chang, Kevin, Cook, Aaron M. , Schadler, Aric D. , Witenko, Corey J. , Bissell, Brittany D.

Mayo Clinic

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | April 6, 2023 | Volume: 6 | Issue: 5 | Pages: 446-457

10.1002/jac5.1788 Get It

AbstractIntroductionLetters of recommendation (LORs) are important in pharmacy residency applications. Applicant gender, among other variables, may result in implicit biases that could impact LORs and/or residency attainment. This study hypothesized that LORs have linguistic gender differences in pharmacy residency applications.ObjectivesThe primary objective was to determine if gender‐linguistic differences exist in applicants' LORs. Gender was assessed via the pronouns utilized within the applications. The secondary outcome was to assess LOR linguistic and demographic differences between candidates who did and did not receive interviews.MethodsThis was a multiyear, multicenter study involving postgraduate year one (PGY1) applicants to participating pharmacy residency programs. Demographic data were extracted using the PhORCAS (Pharmacy Online Residency Centralized Application Service) WebADMIT (Admissions Management System) portal, and LORs were analyzed by validated linguistics processing software.ResultsA total of 7529 LORs and 2383 applicants (28.5% men, 71.5% women) were included. Women candidates had higher mean number of awards (4.71 vs. 4.1, p = 0.001) and leadership positions (4.87 vs. 4.48, p = 0.019). Compared with men candidates, women had statistically significantly higher levels of clout (p < 0.001), positive emotion (p = 0.01), social processes (p < 0.001), prosocial behavior (p = 0.002), and social referents (p < 0.001). Women also had lower authenticity compared with men candidates (p < 0.001). Two thousand and one hundred twenty applicants included in the secondary analysis found no difference in offer to interview between women and men candidates (odds ratio [OR] 1.173 [95% confidence interval (CI) 0.895–1.57], p = 0.247).ConclusionsMen and women applicants' LORS differed in specific linguistic variables, although offer to interview was not significantly different based on gender. LOR writers and programs should consider implicit biases that could affect residency offers to interview.
Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry
Chang, Kevin Y. , Duval, Sue , Badesch, David B., Bull, Todd M., Chakinala, Murali M. , Marco, Teresa De , Frantz, Robert P. , Hemnes, Anna R. , Mathai, Stephen C. , Ryan, John , Thenappan, Thenappan , Allen, Roblee P., Bartolome, Sonja, Cadaret, Linda , Eggert, Michael, Elwing, Jean , Fineman, Jeffrey R. , Foley, Raymond , Ford, H. James , Hirsch, Russel, Grinnan, James, Kennedy, Jamie L.W. , Klinger, James R. , Mazimba, Sula , Ramani, Gautam , Raina, Amresh, Runo, James , Swisher, John W. , Varghese, Nidhy P. , White, R.J., Yung, Delphine , Zamanian, Roham T. , Zwicke, Dianne, De Marco, Teresa , Hemnes, Anna , Ryan, John J , Thenappan, Thenappan , Frantz, Robert P , Mathai, Stephen C , Rosenzweig, Erika B. , Benza, Raymond L. , Hirsch, Russel , Ivy, D. Dunbar , Kawut, Steven M. , Leary, Peter J. , White, R. James , Williamson, Timothy L.

Mayo Clinic

Journal of the American Heart Association | April 27, 2022 | Volume: 11 | Issue: 9 | Pages: No page available

10.1161/jaha.121.024969 | PMID 35475351 Get It

Background Current mortality data for pulmonary arterial hypertension (PAH) in the United States are based on registries that enrolled patients prior to 2010. We sought to determine mortality in PAH in the modern era using the PHAR (Pulmonary Hypertension Association Registry). Methods and Results We identified all adult patients with PAH enrolled in the PHAR between September 2015 and September 2020 (N=935). We used Kaplan‐Meier survival analysis and Cox proportional hazards models to assess mortality at 1, 2, and 3 years. Patients were stratified based on disease severity by 3 validated risk scores. In treatment‐naïve patients, we compared survival based on initial treatment strategy. The median age was 56 years (44–68 years), and 76% were women. Of the 935 patients, 483 (52%) were ≤6 months from PAH diagnosis. There were 121 deaths (12.9%) during a median follow‐up time of 489 days (281–812 days). The 1‐, 2‐, and 3‐year mortality was 8% (95% CI, 6%–10%), 16% (95% CI, 13%–19%), and 21% (95% CI, 17%–25%), respectively. When stratified into low‐, intermediate‐, and high‐risk PAH, the mortality at 1, 2, and 3 years was 1%, 4% to 6%, and 7% to 11% for low risk; 7% to 8%, 11% to 16%, and 18% to 20% for intermediate risk; and 12% to 19%, 22% to 38%, and 28% to 55% for high risk, respectively. In treatment‐naïve patients, initial combination therapy was associated with better 1‐year survival (adjusted hazard ratio, 0.43 [95% CI, 0.19–0.95]; P =0.037). Conclusions Mortality in the intermediate‐ and high‐risk patients with PAH remains unacceptably high in the PHAR, suggesting the importance for early diagnosis, aggressive use of available therapies, and the need for better therapeutics.
Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights from the Pulmonary Hypertension Association Registry
Chang, Kevin Y. , Badesch, D.B., Bull, T.M., Chakinala, Murali M. , Marco, Teresa De , Mathai, S.C., Ryan, J.J., Mathai, Stephen C. , Mathai, Stephen C , Duval, Sue , Frantz, Robert P. , Hemnes, Anna R. , Rosenzweig, Erika B. , Thenappan, Thenappan

Mayo Clinic

D3. D003 COME TOGETHER - CLINICAL ADVANCES IN PULMONARY HYPERTENSION: LESSONS FROM BEST ABSTRACTS | May 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A1181-A1181

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1181 Get It

Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment
Huang, Yinshi, Nahar, Sabikun , Nakagawa, Akifumi, Fernández‐Barrena, Maite G. , Mertz, Jennifer A. , Bryant, Barbara M. , Adams, Curtis E., Alt, Kate N. Von, Chang, Kevin K. , Conery, Andrew R. , Hatton, Charlie , Sims, Robert J., Fernández-Zapico, Martín E. , Wang, Xingpeng , Lillemoe, Keith D. , Castillo, Carlos Fernández‐del , Warshaw, Andrew L. , Thayer, Sarah P. , Mino-Kenudson, Mari A. , Liss, Andrew S

Mayo Clinic

Clinical Cancer Research | May 12, 2016 | Volume: 22 | Issue: 16 | Pages: 4259-4270

10.1158/1078-0432.ccr-15-2068 | PMID 27169995 Get It

Abstract Purpose: The initiation, progression, and maintenance of pancreatic ductal adenocarcinoma (PDAC) results from the interplay of genetic and epigenetic events. While the genetic alterations of PDAC have been well characterized, epigenetic pathways regulating PDAC remain, for the most part, elusive. The goal of this study was to identify novel epigenetic regulators contributing to the biology of PDAC. Experimental Design: In vivo pooled shRNA screens targeting 118 epigenetic proteins were performed in two orthotopic PDAC xenograft models. Candidate genes were characterized in 19 human PDAC cell lines, heterotopic xenograft tumor models, and a genetically engineered mouse (GEM) model of PDAC. Gene expression, IHC, and immunoprecipitation experiments were performed to analyze the pathways by which candidate genes contribute to PDAC. Results: In vivo shRNA screens identified BRD2 and BRD3, members of the BET family of chromatin adaptors, as key regulators of PDAC tumor growth. Pharmacologic inhibition of BET bromodomains enhanced survival in a PDAC GEM model and inhibited growth of human-derived xenograft tumors. BET proteins contribute to PDAC cell growth through direct interaction with members of the GLI family of transcription factors and modulating their activity. Within cancer cells, BET bromodomain inhibition results in downregulation of SHH, a key mediator of the tumor microenvironment and canonical activator of GLI. Consistent with this, inhibition of BET bromodomains decreases cancer-associated fibroblast content of tumors in both GEM and xenograft tumor models. Conclusions: Therapeutic inhibition of BET proteins offers a novel mechanism to target both the neoplastic and stromal components of PDAC. Clin Cancer Res; 22(16); 4259–70. ©2016 AACR.